Yet another suit alleges an ERISA fiduciary breach regarding the administration of a corporate healthcare plan.

Improving Global Outcomes organization's updates to its 2024 guidelines expand SGLT2 inhibitor use and refine chronic kidney ...

Total Revenue Grew 186% Y/Y to $332.3 Million; FY24 U.S. Net Product Revenue Grew 48% Y/Y to $115.7 Million ––Q4 Total Revenue Grew 114% ...

Ezetimibe (Zetia) is the first available treatment from this class of drugs. According to the American Heart Association, it’s the second most commonly used cholesterol-lowering medication after ...

Merck , known as MSD outside of the United States and Canada, today announced that new clinical and outcomes research data will be presented at the American College of Cardiology's Annual Scientific ...

An acute necrotising myopathy is a distinct form of uncommon muscle disease characterised by the rapid advancement of ...

Use of cystatin C and SGLT2 inhibitors were highlighted in the Kidney Disease: Improving Global Outcomes (KDIGO) organization ...

We used the proceeds from the loan and approximately ... I should really not be starting these patients going from a statin to ezetimibe. I should be going right to NEXLIZET.

NICE estimates that around 300,000 people could be eligible for treatment with Leqvio (inclisiran), and use of the drug will ... like Organon's Ezetrol (ezetimibe) and PCSK9 antibodies Praluent ...

Both the European and FDA approvals cover use of the drug to lower LDL cholesterol ... both alone and in combination with ezetimibe. Analysts have previously suggested that Nexletol/Nilemdo ...